Loading…
Loading…
TRGNF (Transgene S.A.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Expansion into Early-Stage NSCLC Transcript
Transgene SA (TRGNF) Q4 2025 Earnings Call Transcript
Strasbourg, France, 27 November 2025, 00:15 a.m. CET – Transgene (Euronext Paris: TNG) had requested the suspension of trading of its shares (ISIN: FR0005175080) on Euronext Paris as from Wednesday, 26 November 2025, before market opening, pending the publication of the results of its capital increase.
Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26, 2025, before the markets open, pending the publication of the results of its capital increase.
Strasbourg, France, November 25, 2025, 7:45 p.m. CET – Transgene (Euronext Paris: TNG) has requested Euronext Paris to suspend trading of its shares (ISIN: FR0005175080) as of Wednesday, November 26, 2025, before the markets open, pending the publication of the results of its capital increase.
Transgene SA (OTC:TRGNF) Discusses TG4050 Phase I Immunological Data in Head and Neck Cancer from SITC Presentation November 14, 2025 10:00 AM EST Company Participants Lucie Larguier - VP & Chief Financial Officer Alessandro Riva - CEO & Chairman of the Board Katell Bidet Huang Conference Call Participants Chiara Montironi Amara Singh Peter Kelleher Presentation Operator Good morning, and welcome to the Transgene conference call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Transgene website following the event.
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy LUND, SE / ACCESS Newswire / October 20, 2025 / Transgene (Euronext Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class antibodies for cancer immunotherapy, are jointly presented a poster at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting on updated clinical results and positive antitumoral activity of BT-001 in patients with advanced refractory tumors. The data show that intra-tumoral (IT) BT-001 injection in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) intravenous (IV) anti-PD-1 therapy KEYTRUDA® (pembrolizumab [1] ), was well tolerated and showed positive local, abscopal and sustained antitumoral activity in injected and non-injected lesions.
BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class antibodies for cancer immunotherapy, jointly presented a poster at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting on updated clinical results and positive antitumoral activity of BT-001 in patients with advanced refractory tumors.
No recent filings indexed.